(Q48467310)

English

Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial

scientific article published on 20 July 2006

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/16855865

Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/16855865

oligodendroglioma

1 reference

based on heuristic

inferred from title

0 references

author name string

A Taliansky-Aronov

1

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/16855865

F Bokstein

2

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/16855865

I Lavon

3

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/16855865

T Siegal

4

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/16855865

publication date

20 July 2006

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/16855865

Journal of Neuro-Oncology

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/16855865

79

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/16855865

2

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/16855865

153-157

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/16855865

Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-005-9020-1

21 January 2018

Long-term outcome of oligodendrogliomas

1 reference

https://api.crossref.org/works/10.1007%2FS11060-005-9020-1

21 January 2018

Chemotherapy of anaplastic oligodendroglial tumours

1 reference

https://pubmed.ncbi.nlm.nih.gov/16855865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16855865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16855865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16855865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16855865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aggressive oligodendroglioma: a chemosensitive tumor

1 reference

https://pubmed.ncbi.nlm.nih.gov/16855865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16855865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diagnosis and management of oligodendroglioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16855865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16855865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11060-005-9020-1

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/16855865

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/16855865

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48467310&oldid=2209496240"